Effects of Personalized Cardiac Rehabilitation on miRNAs and Biochemical Biomarkers in Patients With Coronary Artery Disease
Changes in Specific miRNAs and Biochemical Biomarkers Following Personalized Cardiac Rehabilitation in Patients With Coronary Artery Disease
This prospective interventional study aims to investigate changes in specific microRNAs (miRNAs) and biochemical biomarkers following a personalized cardiac rehabilitation program in patients with coronary artery disease. A total of 46 participants aged 35-75 years who have undergone percutaneous coronary intervention or coronary artery bypass graft surgery and are eligible for cardiac rehabilitation will be included. Participants will complete a structured, individualized cardiac rehabilitation program lasting 6-8 weeks. Clinical assessments, cardiopulmonary exercise testing, and blood-based biomarker measurements will be performed before and after the rehabilitation program. The primary objective is to determine changes in miRNA and biochemical biomarker levels after cardiac rehabilitation and to evaluate the relationship between these changes and clinical improvement. The findings may contribute to a better understanding of biological responses to cardiac rehabilitation and support the development of more personalized rehabilitation strategies.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Vural KAVUNCU, Prof. Dr.
- Numero di telefono: 90 505 777 43 06
- Email: vural.kavuncu@ksbu.edu.tr
Backup dei contatti dello studio
- Nome: Meltem ÇOBAN, Dr.
- Numero di telefono: +90 544 284 42 58
- Email: meltem.368@hotmail.com
Luoghi di studio
-
-
-
Kütahya, Turchia (Türkiye), 43020
- Kutahya Health Sciences University
-
Contatto:
- Vural KAVUNCU, Prof. Dr.
- Numero di telefono: 1111 02742630043
- Email: vural.kavuncu@ksbu.edu.tr
-
Investigatore principale:
- Fatima YAMAN, Assoc. Prof
-
Investigatore principale:
- Meltem ÇOBAN, Dr.
-
Sub-investigatore:
- Merve AKDENİZ LEBLEBİCİER, Assoc. Prof
-
Sub-investigatore:
- Mevlüt DEMİR, Assoc. Prof
-
Sub-investigatore:
- Cansu OZBAYER, Prof. Dr.
-
Sub-investigatore:
- Fatih KAR, Assoc. Prof.
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Stable coronary artery disease
- History of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
- Referred and considered clinically eligible for a structured cardiac rehabilitation program
- Achievement of a respiratory quotient (RQ) of at least 1.0 during the baseline cardiopulmonary exercise test
- Ability and willingness to participate in the study and complete the cardiac rehabilitation program
Exclusion Criteria:
- Symptoms or signs of myocardial ischemia
- Significant left ventricular outflow tract obstruction
- Ventricular arrhythmia
- Significant valvular heart disease
- Uncontrolled hypertension
- Severe comorbid conditions, including end-stage renal disease, advanced liver disease, or chronic inflammatory disease
- Active malignancy
- Physical limitations preventing full participation in exercise, including severe musculoskeletal disorders or major orthopedic or neurological comorbidities
- Body mass index greater than 35 kg/m²
- History of orthopedic surgery within the previous 6 months
- Failure to comply with exercise testing or training procedures, or attendance of less than 80% of the rehabilitation program
- Use of medications known to directly alter miRNA expression, such as certain immunosuppressive agents or chemotherapy drugs
- Known psychiatric disorder
- Presence of a permanent cardiac pacemaker
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Personalized Cardiac Rehabilitation Group
Participants will undergo a structured, individualized cardiac rehabilitation program lasting 6-8 weeks. Exercise intensity and workload will be prescribed according to each participant's baseline cardiopulmonary exercise test results, including peak oxygen uptake and maximal workload. The rehabilitation program will be tailored to the participant's clinical status and exercise capacity. Clinical assessments, cardiopulmonary exercise testing, and blood sampling for miRNA and biochemical biomarker analyses will be performed before and after completion of the rehabilitation program. |
Participants will receive a structured, individualized cardiac rehabilitation program consisting of 30 supervised aerobic exercise sessions performed on a cycle ergometer. Each session will last approximately 45-60 minutes and will include a 5-10-minute low-intensity warm-up, an individualized aerobic exercise phase, and a gradual cool-down period. Exercise intensity will be prescribed according to baseline cardiopulmonary exercise testing and maximal exercise capacity. Training intensity will begin at approximately 40-50% of VO₂max, progress to 60-70% of VO₂max corresponding to a Borg Rating of Perceived Exertion of approximately 12-15, and may reach approximately 80% of VO₂max when clinically appropriate and well tolerated. Exercise workload will be individualized based on the maximal workload achieved during baseline cardiopulmonary exercise testing. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in miRNA Expression Levels
Lasso di tempo: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Changes in the expression levels of miR-21, miR-126, miR-92a, miR-1, miR-155, and miR-133a will be assessed using quantitative real-time polymerase chain reaction (qRT-PCR) before and after completion of the cardiac rehabilitation program. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Inflammatory, Cardiac, and Oxidative Stress Biomarkers
Lasso di tempo: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Changes in circulating levels of NT-proBNP, troponins, hs-CRP, IL-6, TNF-α, ST2, semaphorins, MDA, ADMA, and eNOS will be assessed before and after the cardiac rehabilitation program. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Peak Oxygen Uptake (VO₂max)
Lasso di tempo: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Peak oxygen uptake will be assessed using cardiopulmonary exercise testing (CPET) performed on a cycle ergometer. VO₂max will be recorded in mL/kg/min as an indicator of maximal aerobic exercise capacity. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Maximum Exercise Workload
Lasso di tempo: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Maximum exercise workload achieved during cardiopulmonary exercise testing will be recorded in watts. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Six-Minute Walk Test Distance
Lasso di tempo: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Functional exercise capacity will be assessed using the Six-Minute Walk Test. Participants will be instructed to walk as far as possible without running along a 30-meter corridor for six minutes. The total distance walked will be recorded in meters. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Resting Heart Rate
Lasso di tempo: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Resting heart rate will be measured before cardiopulmonary exercise testing and recorded in beats per minute. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Maximum Heart Rate
Lasso di tempo: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Maximum heart rate achieved during cardiopulmonary exercise testing will be recorded in beats per minute. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Health-Related Quality of Life
Lasso di tempo: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36) before and after the cardiac rehabilitation program. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Vural KAVUNCU, Prof. Dr., Kutahya Health Sciences University
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- KSBÜ-CR-miRNA-
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
"Individual participant data will not be shared because the study includes genetic and biomarker data that may raise privacy and confidentiality concerns."
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .